In the United States alone, more than 795,000 people experience a stroke each year, which is about one in every 40 seconds, causing 1 in 6 deaths from cardiovascular disease. Globally, stroke is a leading cause of disability and death: in 2021, there were 11.9 million new strokes and 93.8 million people living with stroke.
Brainomix wants to change that through the use of artificial intelligence: the company, which spun-out from the University of Oxford, creates AI-powered software solutions to allow for better treatment decisions in stroke and lung fibrosis. Its Brainomix 360 Stroke platform, which is FDA-cleared and CE-marked, is a collection of tools that use its AI algorithms to support doctors by providing real-time interpretation of brain scans to help guide treatment and transfer decisions for stroke patients.
Brainomix already has offices in the UK, Ireland and the USA, with operations in more than 30 countries, and now will be able to expand stroke care for patients across Western Europe thanks to a partnership with medical technology company Medtronic Neurovascular, announced on Thursday, which will integrate AI solutions into clinical practice.
The partnership will bring together Brainomix’s AI-powered imaging technology with Medtronic’s expertise in neurovascular treatments, with the goal of supporting faster, more accurate diagnoses.
The Brainomix 360 Stroke platform is powered by AI algorithms that provide real-time interpretation of brain scans. That includes e-ASPECTS, which can detect and measure both Large Vessel Occlusion (LVO) and hyperdense volumes; e-CTA, which standardizes the assessment of collaterals, with automatic LVO detection in CTA scans, and allows graphical visualization of CTA acquisition timing; and e-CTP, which automatically estimates core and penumbra volumes.
The platform also has a mobile app, which allows physicians to access, review and share images and patient data across a network, send messages, make calls directly from the app, and flag patients eligible for thrombectomy.
Brainomix 360 Stroke was studied in the largest real-world evaluation of stroke AI, involving data from more than 450,000 patients across England over a five year period, showing a doubling of thrombectomy rates in Brainomix sites, and an additional 37% increase compared with non-evaluation sites.
The platform was also associated with an additional 50% increase in the number of patients receiving mechanical thrombectomy, while also reducing door-in-door-out (DIDO) time by nearly 50 minutes, in an evaluation of stroke AI imaging involving more than 83,000 patients at 26 sites over a three year period.
By partnering with Medtronic, Brainomix will use the company’s presence in Western Europe to accelerate the adoption of its AI technology.
“This partnership with Medtronic is a natural fit, with the leading neurovascular device provider joining forces with the leading stroke AI imaging partner, both aligned around a mutual commitment towards improving stroke care for all patients,” Dr. Michalis Papadakis, CEO and Co-Founder of Brainomix, said in a statement.
“We have demonstrated that our software impacts treatment rates, and working with Medtronic, we now have an opportunity together to deliver a solution for stroke networks across Europe that will enable more patients to get access to vital stroke treatments.”
(Image source: brainomix.com)
